New Zealand markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
132.73+0.42 (+0.32%)
At close: 4:03PM EDT
132.73 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close132.31
Open132.72
Bid132.76 x 900
Ask132.39 x 3200
Day's range131.79 - 133.00
52-week range86.43 - 142.64
Volume471,634
Avg. volume854,398
Market cap22.678B
Beta (5Y monthly)1.39
PE ratio (TTM)42.68
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast

    SOMERSET, N.J., October 20, 2021--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2022 ended September 30, 2021, before the market open on Tuesday, November 2, 2021. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET

  • Business Wire

    Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030

    SOMERSET, N.J., September 23, 2021--Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the "Operating Subsidiary"), priced a private offering (the "Private Offering") of $650 million in aggregate principal amount of 3.500% senior unsecured notes due

  • Business Wire

    Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030

    SOMERSET, N.J., September 23, 2021--Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the "Operating Subsidiary"), intends to offer, subject to market and other conditions, $450 million in aggregate principal amount of senior unsecured notes due 20